Anti-HLA-A2-MAGE-A4/Anti-CD3 Bispecific Antibody RO7444973

Preferred Label : Anti-HLA-A2-MAGE-A4/Anti-CD3 Bispecific Antibody RO7444973;

NCIt synonyms : HLA-A2-MAGE-A4 x CD3 Bispecific Antibody RO7444973; Anti-HLA-A2-MAGE-A4/CD3 Bispecific Antibody RO7444973; Anti-HLA-A2-MAGE-A4/Anti-CD3 Bispecific Antibody RG6129;

NCIt definition : A bispecific T-cell engaging antibody directed against both the tumor-associated antigen (TAA) human leukocyte antigen (HLA)-A2-restricted, melanoma-associated antigen A4 (MAGE-A4) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A2-MAGE-A4/Anti-CD3 bispecific antibody RO7444973 simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-A2 MAGE-A4 on MAGE-A4-expressing tumor cells. This activates and redirects CTLs to MAGE-A4-expressing tumor cells, which results in the CTL-mediated cell death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.;

Molecule name : RO 7444973; RO-7444973; RG-6129; RG 6129;

NCI Metathesaurus CUI : CL1794269;

Details

Origin ID

C189056;

UMLS CUI

C5706529;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Melanoma-Associated Antigen 4 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients